Brooks Laboratories Limited
NSE: BROOKS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Brooks Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Brooks Laboratories Ltd is a pharmaceutical company specialising in the manufacturing and marketing of pharmaceutical formulations. The company operates primarily within the critical care segment and maintains EU GMP and ISO 9001:2008 certifications.
Business Model
The company operates on a contract manufacturing basis, providing pharmaceutical formulation services to clients. It leverages its certified manufacturing facilities to cater to the critical care market.
Growth Outlook
Growth is expected to be driven by the company's focus on the critical care segment and its adherence to international quality standards like EU GMP. Future expansion depends on securing further contract manufacturing agreements.
Key Risks
- Regulatory Compliance. Failure to maintain international quality certifications like EU GMP could lead to the loss of key contracts and market access.
- Client Concentration. As a contract manufacturer, the company may be vulnerable to the loss of major clients or fluctuations in their demand.
- Sector Competition. The pharmaceutical contract manufacturing industry is highly competitive, which may exert pressure on profit margins.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact operational profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Brooks Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹86 Cr
TTM · consolidated
NET PROFIT
₹25 Cr
TTM · consolidated
EPS
₹8.35
TTM · consolidated
RETURN ON EQUITY
23.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.2%
TTM · consolidated
P/E
6.6x
Q4 FY26 · consolidated
EV/EBITDA
22.0x
Q4 FY26 · consolidated
EBITDA MARGIN
9.6%
TTM · consolidated
NET PROFIT MARGIN
7.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Brooks Laboratories LimitedBROOKS | ₹180 Cr | 6.56 | 21.97 | 3.9% | 9.6% | 23.6% | 6.2% | -58.4% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Brooks Laboratories Limited
NSE: BROOKS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Brooks Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Brooks Laboratories Ltd is a pharmaceutical company specialising in the manufacturing and marketing of pharmaceutical formulations. The company operates primarily within the critical care segment and maintains EU GMP and ISO 9001:2008 certifications.
Business Model
The company operates on a contract manufacturing basis, providing pharmaceutical formulation services to clients. It leverages its certified manufacturing facilities to cater to the critical care market.
Growth Outlook
Growth is expected to be driven by the company's focus on the critical care segment and its adherence to international quality standards like EU GMP. Future expansion depends on securing further contract manufacturing agreements.
Key Risks
- Regulatory Compliance. Failure to maintain international quality certifications like EU GMP could lead to the loss of key contracts and market access.
- Client Concentration. As a contract manufacturer, the company may be vulnerable to the loss of major clients or fluctuations in their demand.
- Sector Competition. The pharmaceutical contract manufacturing industry is highly competitive, which may exert pressure on profit margins.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact operational profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Brooks Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹86 Cr
TTM · consolidated
NET PROFIT
₹25 Cr
TTM · consolidated
EPS
₹8.35
TTM · consolidated
RETURN ON EQUITY
23.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.2%
TTM · consolidated
P/E
6.6x
Q4 FY26 · consolidated
EV/EBITDA
22.0x
Q4 FY26 · consolidated
EBITDA MARGIN
9.6%
TTM · consolidated
NET PROFIT MARGIN
7.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26